Geetha Reddy, MD
Cardiovascular Disease · Libertyville, ILNPI 1174545453
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,667 of the $1,940 with a category attached, or 85.9%. It is spread thinly across 18 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.
Across 87 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$457
- Amgen$313
- Astellas Pharma US Inc$259
- Boston Scientific$174
- Merck$129
- Johnson & Johnson$106
- plus $502 from 12 others
Across 97 payments — averaging $3043.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$197K
- Boehringer Ingelheim International GmbH$70K
- Boehringer Ingelheim Pharma GmbH & Co.kg$28K
What the payments were for
- Food & beverage$1,66786%
- Education$27314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 26 | $457 |
| Amgen | 18 | $313 |
| Astellas Pharma US Inc | 3 | $259 |
| Boston Scientific | 4 | $174 |
| Merck | 7 | $129 |
| Johnson & Johnson | 5 | $106 |
| AstraZeneca | 4 | $93 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $93 |
| Esperion Therapeutics, Inc. | 3 | $66 |
| Edwards Lifesciences | 2 | $46 |
| Pfizer | 2 | $42 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$121
How this compares
$1,940 in reported general payments places this provider in the 55th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $240,808 |
| EntrestoSacubitril/Valsartan | 72 | $92,099 |
| XareltoRivaroxaban | 36 | $41,732 |
| Repatha SureclickEvolocumab | 30 | $31,725 |
| JardianceEmpagliflozin | 21 | $23,774 |
| Metoprolol Succinate | 377 | $6,273 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $3,970 |
| Clonidine | 28 | $3,739 |
| Amlodipine Besylate | 278 | $2,695 |
| Atorvastatin Calcium | 197 | $2,152 |
| Rosuvastatin Calcium | 116 | $1,541 |
| Losartan Potassium | 121 | $1,044 |
| Torsemide | 53 | $1,007 |
| Nebivolol Hcl | 12 | $992 |
| Hydralazine Hcl | 54 | $935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $240,808200 claims |
| NovartisEntresto | $457 | $92,09972 claims |
| Johnson & JohnsonXarelto | $106 | $41,73236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Libertyville
- Robert KochLibertyville$298K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.